How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.

[1]  J. André Knottnerus,et al.  General Introduction: Evaluation of Diagnostic Procedures , 2009 .

[2]  Frank Buntinx,et al.  The evidence base of clinical diagnosis , 2008 .

[3]  S. Skates,et al.  Pooling of Case Specimens to Create Standard Serum Sets for Screening Cancer Biomarkers , 2007, Cancer Epidemiology Biomarkers & Prevention.

[4]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[5]  Marc Buyse,et al.  Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.

[6]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[7]  J. Knottnerus,et al.  Are we at the start of a new era in diagnostic research? , 2006, Journal of clinical epidemiology.

[8]  B. H. Patterson,et al.  Evaluating markers for the early detection of cancer: overview of study designs and methods , 2006, Clinical trials.

[9]  E. Petricoin,et al.  Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. , 2005, The Journal of clinical investigation.

[10]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[11]  G. MacGrogan,et al.  When will more useful predictive factors be ready for use? , 2005, Breast.

[12]  Richard Simon,et al.  Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Hede.  $104 million proteomics initiative gets green light. , 2005, Journal of the National Cancer Institute.

[14]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[15]  Annette M. Molinaro,et al.  Prediction error estimation: a comparison of resampling methods , 2005, Bioinform..

[16]  Hongyu Zhao,et al.  Serum protein markers for early detection of ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Simon Frantz,et al.  An array of problems , 2005, Nature reviews. Drug discovery.

[18]  R. Warnke,et al.  Immune signatures in follicular lymphoma. , 2005, The New England journal of medicine.

[19]  Fredric Cohen,et al.  Macro trends in pharmaceutical innovation , 2005, Nature Reviews Drug Discovery.

[20]  D. Ransohoff.  Lessons from controversy: ovarian cancer screening and serum proteomics. , 2005, Journal of the National Cancer Institute.

[21]  Emanuel F Petricoin,et al.  Importance of communication between producers and consumers of publicly available experimental data. , 2005, Journal of the National Cancer Institute.

[22]  Jeffrey S. Morris,et al.  Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. , 2005, Journal of the National Cancer Institute.

[23]  J. Ioannidis.  Microarrays and molecular research: noise discovery? , 2005, The Lancet.

[24]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[25]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[26]  Upender Manne,et al.  The Need for Review and Understanding of SELDI/MALDI Mass Spectroscopy Data Prior to Analysis , 2005, Cancer informatics.

[27]  Jeffrey S. Morris,et al.  Bias, Randomization, and Ovarian Proteomic Data: A Reply to “Producers and Consumers” , 2005 .

[28]  Eric McNulty.  Justo a tiempo para Navidad , 2005 .

[29]  Johannes B Reitsma,et al.  A systematic review finds that diagnostic reviews fail to incorporate quality despite available tools. , 2005, Journal of clinical epidemiology.

[30]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[31]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[32]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[33]  Sarah R. Edmonson,et al.  High-resolution serum proteomic patterns for ovarian cancer detection. , 2004, Endocrine-related cancer.

[34]  Eliot Marshall,et al.  Getting the Noise Out of Gene Arrays , 2004, Science.

[35]  Ross Prentice,et al.  Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. , 2004, Pharmacogenomics.

[36]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[37]  Eleftherios P. Diamandis,et al.  OvaCheck: doubts voiced soon after publication , 2004, Nature.

[38]  Erika Check,et al.  Proteomics and cancer: Running before we can walk? , 2004, Nature.

[39]  K. Garber.  Debate rages over proteomic patterns. , 2004, Journal of the National Cancer Institute.

[40]  David F. Williams.  The critical path to medical innovation. , 2004, Medical device technology.

[41]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[42]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[43]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[44]  J. Couzin.  The New Math of Clinical Trials , 2004, Science.

[45]  J. Glimm,et al.  Detection of cancer-specific markers amid massive mass spectral data , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Ioannidis,et al.  Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment , 2003, The Lancet.

[47]  J. Knottnerus,et al.  Assessment of the accuracy of diagnostic tests: the cross-sectional study. , 2003, Journal of clinical epidemiology.

[48]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[49]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[50]  Sridhar Ramaswamy,et al.  DNA microarrays in breast cancer: the promise of personalised medicine , 2003, The Lancet.

[51]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[52]  David F Ransohoff,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[53]  B. Adam,et al.  SELDI-TOF-MS profiling of serum for early detection of colorectal cancer , 2003 .

[54]  E. Diamandis,et al.  Re: Serum proteomic patterns for detection of prostate cancer. , 2003, Journal of the National Cancer Institute.

[55]  D. Ransohoff.  Developing Molecular Biomarkers for Cancer , 2003, Science.

[56]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[57]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[58]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[59]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[60]  David F Ransohoff,et al.  Challenges and opportunities in evaluating diagnostic tests. , 2002, Journal of clinical epidemiology.

[61]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[62]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[63]  Robert A. Weinberg,et al.  Metastasis genes: A progression puzzle , 2002, Nature.

[64]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[65]  D. Ransohoff.  Research opportunity at the interface of molecular biology and clinical epidemiology , 2002 .

[66]  D. Sackett,et al.  The architecture of diagnostic research , 2002, BMJ : British Medical Journal.

[67]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[68]  G. Clark.  Interpreting and integrating risk factors for patients with primary breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[69]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[70]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[71]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[72]  J. Concato.  Challenges in prognostic analysis , 2001, Cancer.

[73]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[74]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[75]  A R Feinstein,et al.  Clinical epidemiological quality in molecular genetic research: the need for methodological standards. , 1999, JAMA.

[76]  C. Mulrow,et al.  Colorectal cancer screening: clinical guidelines and rationale. , 1997, Gastroenterology.

[77]  Robert J. Mayer,et al.  Erratum: Colorectal cancer screening: Clinical guidelines and rationale (Gastroenterology (1997) 112 (594-642)) , 1997 .

[78]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[79]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[80]  D. Rennie,et al.  How to report randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[81]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[82]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[83]  Kenneth F. Schulz,et al.  The CONSORT Statement , 1996 .

[84]  P Glasziou,et al.  Meta-analytic methods for diagnostic test accuracy. , 1995, Journal of clinical epidemiology.

[85]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[86]  L. Breiman,et al.  Submodel selection and evaluation in regression. The X-random case , 1992 .

[87]  P. Burman.  A comparative study of ordinary cross-validation, v-fold cross-validation and the repeated learning-testing methods , 1989 .

[88]  S. Cummings,et al.  Designing Clinical Research: An Epidemiologic Approach , 1988 .

[89]  B. Casto,et al.  Conditions for transformation of human fibroblast cells: an overview. , 1986, Cancer letters.

[90]  A. Feinstein,et al.  Clinical Epidemiology: The Architecture of Clinical Research. , 1987 .

[91]  J. Platt.  Strong Inference: Certain systematic methods of scientific thinking may produce much more rapid progress than others. , 1964, Science.

[92]  H. Marshall McLuhan,et al.  Producers and Consumers , 1961 .